Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

Authors

Institutions

Publication Details

Journal
The Lancet
Published
2024-08-01
DOI
https://doi.org/10.1016/s0140-6736(24)01498-3
Citations
190
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
67.96

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

Ildiko Lingvay, A. Michael Lincoff, Helen M. Colhoun, John Eric Deanfield et al.
190 citations
The Lancet
Diabetes Treatment and Management
67.96
article

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

Ildiko Lingvay, A. Michael Lincoff, Helen M. Colhoun, John Eric Deanfield, Assen Goudev, Benjamin M. Scirica, Jorge Plutzky, Mikhail Kosiborod, Peter Weeke, G Kees Hovingh, Steven E. Kahn, Chim C. Lang, Søren Hardt‐Lindberg, Subodh Verma, Miguel Urina‐Triana, Ofir Frenkel, Donna H. Ryan, Mikko Pietilä, Scott S. Emerson, Søren Rasmussen
article en
190 citations

Abstract

No abstract available for this paper.
The LancetVol. 404(10454)
Pennington Biomedical Research Center (US), Brigham and Women's Hospital (US), St. Michael's Hospital (CA), Harvard University (US), University of Turku (FI), University of Dundee (GB), University of Toronto (CA), Novo Nordisk (Denmark) (DK), University of Washington (US), Queen Giovanna Hospital (BG), Turku University Hospital (FI), Cleveland Clinic Lerner College of Medicine (US), VA Puget Sound Health Care System (US), Universidad Simón Bolívar (CO), Saint Luke's Hospital (US), Institute of Genetics and Cancer (GB), Case Western Reserve University (US), University of Missouri–Kansas City (US), University of Edinburgh (GB)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Brigham and Women's Hospital, Alnylam Pharmaceuticals, FibroGen, CSL Behring, Regeneron Pharmaceuticals, TG Therapeutics, Novavax, Intarcia Therapeutics, Amarin Corporation, MannKind Corporation, ReCor Medical, Mylan, BeiGene, Moderna, Insmed, Diabetes UK, European Commission, Novo Nordisk, Shionogi, Servier, H. Lundbeck A/S, Ipsen, Akebia Therapeutics, Esperion Therapeutics, Allergan, Medical Research Council, Daiichi Sankyo Europe
Good health and well-being
Openalex Percentile: Top 0%
Diabetes Treatment and Management
67.96
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.